

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Hatteras Venture Advisors III, LLC</u>  (Last) (First) (Middle) 280 S. MANGUM STREET, SUITE 350  (Street) DURHAM NC 27701  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Clearside Biomedical, Inc. [ CLSD ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) <u>May be part of a 13(d) Group</u>
	3. Date of Earliest Transaction (Month/Day/Year) 01/17/2017	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/17/2017		S		8,366	D	\$8.92 <sup>(1)</sup>	1,774,654	I	See Footnote <sup>(2)</sup>
Common Stock	01/18/2017		S		10,457	D	\$8.64 <sup>(3)</sup>	1,764,197	I	See Footnote <sup>(2)</sup>
Common Stock	01/19/2017		S		6,478	D	\$8.22 <sup>(4)</sup>	1,757,719	I	See Footnote <sup>(2)(5)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person* <u>Hatteras Venture Advisors III, LLC</u>  (Last) (First) (Middle) 280 S. MANGUM STREET, SUITE 350  (Street) DURHAM NC 27701  (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person\*

[Hatteras Ventures Partners III LP](#)

(Last) (First) (Middle)  
280 S. MANGUM STREET, SUITE 350

(Street)  
DURHAM NC 27701

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[Hatteras Venture Affiliates III Lp](#)

(Last) (First) (Middle)  
280 S. MANGUM STREET, SUITE 350

(Street)  
DURHAM NC 27701

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[Crumpler John](#)

(Last) (First) (Middle)  
C/O HATTERAS VENTURES  
280 S. MANGUM STREET, SUITE 350

(Street)  
DURHAM NC 27701

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[INGRAM ROBERT ALEXANDER](#)

(Last) (First) (Middle)  
C/O HATTERAS VENTURES  
280 S. MANGUM STREET, SUITE 350

(Street)  
DURHAM NC 27701

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[LEE KENNETH B JR](#)

(Last) (First) (Middle)  
C/O HATTERAS VENTURES  
280 S. MANGUM STREET, SUITE 350

(Street)  
DURHAM NC 27701

(City) (State) (Zip)

1. Name and Address of Reporting Person*		
<a href="#">Reed Douglas MD</a>		
(Last)	(First)	(Middle)
C/O HATTERAS VENTURES		
280 S. MANGUM STREET, SUITE 350		
(Street)		
DURHAM	NC	27701
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
<a href="#">Thorp Clay</a>		
(Last)	(First)	(Middle)
C/O HATTERAS VENTURES		
280 S. MANGUM STREET, SUITE 350		
(Street)		
DURHAM	NC	27701
(City) (State) (Zip)		

**Explanation of Responses:**

1. This transaction was executed in multiple trades at prices ranging from \$8.68 to \$9.22. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
2. The reportable securities are owned directly by Hatteras Venture Partners III, LP ("HVP") and Hatteras Venture Affiliates III, LP ("HVA"). Hatteras Venture Advisors III, LLC is the general partner of HVP and HVA (the "GP"). The shares directly held by HVP and HVA are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP and HVA. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
3. This transaction was executed in multiple trades at prices ranging from \$8.42 to \$8.79. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
4. This transaction was executed in multiple trades at prices ranging from \$8.01 to \$8.65. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
5. HVP holds 1,611,407 shares and HVA holds 146,312 shares of the Issuer's common stock directly.

[/s/ Thomas A. Allen, attorney-in-fact for Hatteras Venture Advisors III, LLC](#) 01/19/2017

[/s/ Thomas A. Allen, attorney-in-fact for Hatteras Venture Advisors III, LLC, the general partner of Hatteras Venture Partners III, LP](#) 01/19/2017

[/s/ Thomas A. Allen, attorney-in-fact for Hatteras Venture Advisors III, LLC, the general partner of Hatteras Venture Affiliates III, LP](#) 01/19/2017

[/s/ Thomas A. Allen, attorney-in-fact for John C. Crumpler](#) 01/19/2017

[/s/ Thomas A. Allen, attorney-in-fact for Robert A. Ingram](#) 01/19/2017

[/s/ Thomas A. Allen, attorney-in-fact for Kenneth B. Lee](#) 01/19/2017

[/s/ Thomas A. Allen, attorney-in-fact for Douglas Reed](#) 01/19/2017

[/s/ Thomas A. Allen, attorney-in-fact for Clay B. Thorp](#) 01/19/2017

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents that the undersigned hereby constitutes and appoints each of Thomas A. Allen and Andrew J. Gibbons, and each of them acting alone, signing singly, the undersigned's true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director, and/or 10% or more stockholder of Clearside Biomedical, Inc. (the "Company"), Forms ID, 3, 4 and 5 and Schedules 13D or 13G (and any amendments thereto) under Section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended (the "1934 Act") in accordance with the 1934 Act, and the rules promulgated thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form or Schedule (and any amendments thereto) and to file timely such Form or Schedule with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which in the opinion of such attorney-in-fact may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 13(d) or 16(a) of the 1934 Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file such Forms or Schedules with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 18th day of January 2017.

HATTERAS VENTURE ADVISORS III, LLC

By: /s/ Clay B. Thorp  
Name: Clay B. Thorp  
Title: Manager

HATTERAS VENTURE PARTNERS III, LP

By: Hatteras Venture Advisors III, LLC, its general partner

By: /s/ Clay B. Thorp

Name: Clay B. Thorp  
Title: Manager

HATTERAS VENTURE AFFILIATES III, LP

By: Hatteras Venture Advisors III, LLC, its general partner

By: /s/ Clay B. Thorp  
Name: Clay B. Thorp  
Title: Manager

/s/ John C. Crumpler  
John C. Crumpler

/s/ Robert A. Ingram  
Robert A. Ingram

/s/ Kenneth B. Lee  
Kenneth B. Lee

/s/ Douglas Reed  
Douglas Reed

/s/ Clay B. Thorp  
Clay B. Thorp